A splicing donor site point mutation in intron 6 of the plasmin inhibitor (α2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 1, 2003, Pages 107-111

  Hanss, Michel M L ^b   Farcis, Mathilde ^a   Ffrench, Patrick O ^b   De Mazancourt, Philippe ^a   Dechavanne, Marc ^b  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b NONE

Author keywords

2 antiplasmin; Bleeding; Fibrinolysis; Plasmin inhibitor; Tranexamic acid

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIGEN; TRANEXAMIC ACID;

ADULT; ARTICLE; BLEEDING TENDENCY; CASE REPORT; CONTROLLED STUDY; EXON; FAMILIAL DISEASE; FEMALE; GENE SEQUENCE; HETEROZYGOSITY; HORMONE SUBSTITUTION; HUMAN; IMMUNOBLOTTING; INTRON; POINT MUTATION; PRIORITY JOURNAL; RNA SPLICING; SYMPTOMATOLOGY; UTERUS BLEEDING;

ANTIPLASMIN; FAMILY HEALTH; FEMALE; HEMORRHAGE; HETEROZYGOTE; HUMANS; INTRONS; MIDDLE AGED; POINT MUTATION; RNA SPLICE SITES; TRANEXAMIC ACID;

EID: 12244249867     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200301000-00019     Document Type: Article

References (29)

1. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human α2-antiplasmin, a serine protease inhibitor (Serpin). J Biol Chem 1987; 262:1659-1664.
2. Sakata Y, Aoki N. Cross-linking of α2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65:290-297.
3. Sugiyama N, Sasaki T, Iwamoto M, Abiko Y. Binding site of alpha 2-plasmin inhibitor to plasminogen. Biochim Biophys Acta 1988; 952:1-7.
4. Koie K, Ogata K, Kamiya T, Takamatsu J. α2-plasmin inhibitor deficiency (Miyasato disease). Lancet 1978; 2:1334-1336
5. Kluft C, Vellenga E, Brommer EJ. Homozygous α2-antiplasmin deficiency [Letter]. Lancet 1979; 2:206.
6. Yoshioka A, Kamitsuji, H, Takase T, Iida Y, Tsukada S, Mikami S, et al. Congenital deficiency of alpha 2-plasmin inhibitor in three sisters. Haemostasis 1982; 11:176-184.
7. Griffin GC, Mammen EF, Sokol RJ, Perrotta AL, Stoyanovich A, Abildgaard CF. α2-antiplasmin deficiency. An overlooked cause of hemorrhage. Am J Pediatr Hematol Oncol 1993; 15:328-330.
8. Hirosawa S, Nakamura Y, Miura O, Sumi Y, Aoki N. Organisation of the human α2-plasmin inhibitor gene. Proc Natl Acad Sci 1988; 85: 6836-6840.
9. Welch SK, Francke U. Assignment of the human alpha 2-plasmin inhibitor gene (PLI) to chromosome 17, region pter-p12, by PCR analysis of somatic cell hybrids. Genomics 1992; 13:213-214.
10. Holmes WE, Lijnen HR, Nelles L, Kluft C, Nieuwenhuis HK, Rijken DC, et al. α2 antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science 1987; 238:209-211.
11. Miura O, Hirosawa S, Kato A, Aoki N. Molecular basis for congenital deficiency of α2-plasmin inhibitor: a frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 1989; 83:1598-1604.
12. Miura O, Sugahara Y, Aoki N. Hereditary α2-plasmin inhibitor deficiency caused by a transport-deficient mutation (α2-Pl-Okinawa): deletion of glu-137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 1989; 264:18213-18219.
13. Lind B, Thorsen S. A novel missense mutation in the human plasmin inhibitor (alpha-2-antiplasmin) gene associated with a bleeding tendency. Br J Haematol 1999; 107:317-322
14. Yoshinaga H, Hirosawa S, Chung DH, Miyasaka N, Favier R. A novel point mutation of the splicing donor site in the intron 2 of the plasmin inhibitor gene. Thromb Haemost 2000; 84:307-311.
15. Jones AJS, Meunier AM, A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 64:455-463.
16. Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993; 291;623-625.
17. Kluft C, Los P, Jie AF, van Hinsbergh VW, Vellenga E, Jespersen J, et al. The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. Blood 1986; 67: 616-622.
18. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. α2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93:2274-2281.
19. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M, Congenital deficiency of α2-plasmin inhibitor associated with severe haemorrhagic tendency. J Clin Invest 1979; 63:877-884.
20. Lijnen HR, Collen D. Congenital and acquired deficiencies of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3:67-77.
21. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173:1849-1854.
22. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
23. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683-690.
24. Van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83:29-34.
25. Conard J, Gompel A, Pelissier C, Mirabel C, Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 1997; 68:449-453.
26. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992; 2:445-455.
27. Padilla SL, Galle PC, Ellegood JO, Mahesh VB, McDonough PG. Plasminogen in peritoneal fluid: a possible nonsteroidal indicator of ovulation. Fertil Steril 1986; 46:1071-1076.
28. Hanss M, Rollet J, Berthezène F, Dechavanne M. Modification of fibrinolysis during hormonal conversion of transsexual XX→XY patients [Abstract]. Fibrinolysis 1996; 10 (Suppl 3):109.
29. Favier R, Aoki N, de Moerloose P. Congenital α(2)-plasmin inhibitor deficiencies: a review. Br J Haematol 2001; 114:4-10.